Dahl Edgar is a professor at the Institute of Pathology, Medical Faculty, RWTH Aachen University, Aachen, Germany. He is head of the Molecular Oncology Group and scientific director of the RWTH centralized Biomaterial Bank (RWTH cBMB). He completed his Ph.D. studies at Rheinische Friedrich-Wilhelms-Universität Bonn, Germany. From 1994 to 1997, he held a postdoc position at the GSF Research Center Munich; Institute of Mammalian Genetics. He received a habilitation in molecular pathology at the Rheinisch-Westfälische Technische Hochschule Aachen, Germany, in 2006. His research interests are class 2 tumor suppressor genes, epigenetic therapies, drug development for personalized cancer treatment, and tumor suppressor mimetics.